News >

Erlotinib Linked to Improved Survival in HNSCC

Jason Harris
Published: Sunday, Jul 30, 2017

Adding erlotinib (Tarceva) to platinum-based chemotherapy resulted in a 3.3-month advantage in overall survival (OS) and a 1.7-month advantage in progression-free survival (PFS) for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

The incidence of grade 2 to 5 adverse events (AEs) was greater in the erlotinib arm. The most common grade 2 to 5 AEs in the erlotinib group versus the chemotherapy-alone arm were rash (48% vs 7%), fatigue (47% vs 31%), nausea (40% vs 24%), and diarrhea (33% vs 17%). Only fatigue (31%) and nausea (24%) crossed the ≥20% threshold for grade 2 to 5 AEs in the placebo group.
William NW, Feng L, Kies MS, et al. Randomized, double-blind, placebo-controlled, phase II trial of first-line platinum/docetaxel with or without erlotinib (E) in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinomas (HNSCCs). J Clin Oncol. 35, 2017 (suppl; abstr 6017).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication